CN108671020A - A kind of collunarium slowing down Rhinitis Symptoms and its application - Google Patents
A kind of collunarium slowing down Rhinitis Symptoms and its application Download PDFInfo
- Publication number
- CN108671020A CN108671020A CN201810425278.1A CN201810425278A CN108671020A CN 108671020 A CN108671020 A CN 108671020A CN 201810425278 A CN201810425278 A CN 201810425278A CN 108671020 A CN108671020 A CN 108671020A
- Authority
- CN
- China
- Prior art keywords
- collunarium
- water
- slowing down
- rhinitis symptoms
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 49
- 208000024891 symptom Diseases 0.000 title claims abstract description 48
- 229940105902 mint extract Drugs 0.000 claims abstract description 44
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims abstract description 29
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 26
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 26
- 239000011570 nicotinamide Substances 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940116229 borneol Drugs 0.000 claims abstract description 23
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000470 constituent Substances 0.000 claims abstract description 15
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 claims abstract 4
- DQAIZGWCKXJRSP-UHFFFAOYSA-N 2-tert-butyl-1,3-thiazole Chemical class CC(C)(C)C1=NC=CS1 DQAIZGWCKXJRSP-UHFFFAOYSA-N 0.000 claims description 24
- 210000003928 nasal cavity Anatomy 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- 239000002504 physiological saline solution Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 claims 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- QOJMQILDLLFGEE-UHFFFAOYSA-N 2-butyl-1,3-thiazole Chemical group CCCCC1=NC=CS1 QOJMQILDLLFGEE-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000002585 base Substances 0.000 description 43
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 13
- 238000004140 cleaning Methods 0.000 description 10
- 210000001331 nose Anatomy 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 8
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 230000010355 oscillation Effects 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 208000000592 Nasal Polyps Diseases 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 208000016366 nasal cavity polyp Diseases 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- -1 emgloves Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of collunarium slowing down Rhinitis Symptoms and its application, belongs to medical preparation field.In order to overcome existing collunarium either uncertain therapeutic efficacy cut or in storage time it is short, occur the deficiency of drug effect being greatly lowered in the short time, the present invention provides a kind of collunarium slowing down Rhinitis Symptoms and its application.The active constituent of the collunarium is made of water-soluble mint extract, borneol and N [(4 methyl piperazine base 1) methyl] N (2 tertiary butyl thiazole base 5) niacinamide, it has slows down Rhinitis Symptoms effect well, combination coptisine can improve the transdermal absorption factor of active component on this basis, and then enhance the therapeutic effect of collunarium.Collunarium of the present invention is curative for effect, and preparation stability is high, is appropriate for promoting and applying.
Description
Technical field
The present invention provides a kind of collunarium slowing down Rhinitis Symptoms and its application, belongs to medical preparation field.
Background technology
Allergic rhinitis is also known as allergic rhinitis, is ear-nose-throat department common disease and frequently-occurring disease, belongs to I metallergy diseases
Disease is after atopic individuals contact allergy original, and medium (the predominantly histamine, leukotriene etc.) release mediated by IgE has simultaneously
The nasal membrane chronic inflammatory disease that panimmunity living cells, cell factor participate in.In addition to salt and glucose are generally acknowledged that not
It can cause outside allergy, thousands upon thousands substances are all likely to become the anaphylactogen of various allergic diseases in the world, only cause
The degree of allergy is had nothing in common with each other.Common anaphylactogen is broadly divided into following a few classes：1. inhalant allergen：Pollen, animal
Hair, scurf, indoor dust, dust mite, mould, feather etc..2. eating property allergen：Some drugs, food, especially fish, egg,
Milk and nut fruits etc..3. contact allergen：Wool, dyestuff, cosmetics, emgloves, nickel product.4. injection allergen：
Insect bites venom and some drugs.In recent years, incidence of the allergic rhinitis in city obviously increases, may be with city dirt
It is infected with prodigious relationship.Clinical symptoms are mainly the discomforts such as rhiocnesmus, sneezing, watery nasal discharge, nasal obstruction, and some patients can merge allergy
Membranous conjunctivitis, anaphylaxis sphagitis go out to lose face and itch, are envious, swallowing the symptoms such as itch, cough, checked under nasal endoscopes and see clear water in nasal meatus
Sample nasal mucus, schneiderian membrane oedema, pale, Polypoid changes etc., pathological manifestations are nasal epithelial swelling, and goblet cell increases, hair
Thin blood vessel dilatation, permeability enhancing, eosinophils are around the gland and blood vessel of lamina propria.
The therapy of allergic rhinitis is more at present, but mainly controls symptom with drug, prevents the generation of complication,
But the generation of toxic side effect can be caused by being used for a long time, and it is small to wash nose toxic side effect using nose cola collunarium, especially to being associated with
The patient of heart kidney illness or gestation, when can not use drug therapy, exclusive use collunarium washes nose and also can obviously improve symptom.Nose
Flushing can both remove excessive secretion, can also play the quantity for reducing nasal cavity anaphylactogen, provide the humiture of nasal cavity appropriateness, have
Help impaired schneiderian membrane and restores its proper motion.Row Spraying nasal cavity after rinsing simultaneously, can be such that drug is come into full contact with nasal membrane
Play curative effect of medication.In addition, nasal douche is not only effective to allergic rhinitis, to nasal polyp, nasosinusitis, nasopharyngitis, nasal endoscope operation
Also there is good therapeutic effect afterwards, and toxic side effect is small, is worth clinical application.
Common collunarium is nose cola collunarium currently on the market, is by the number such as sea salt, citric acid and sodium citrate
Kind at being grouped as, matches 240ml water with 1 bag when use, avoid overheat from being subcooled, tepor is advisable.Nose cola collunarium is dissolved with warm water
Afterwards, the functional nasal wash of suitable schneiderian membrane can be formed, there is cleaning, moistening and protection mucous membrane, the work(for promoting nose fibre swing
Energy.The collunarium has the effect of preferably alleviating Rhinitis Symptoms, but its holding time is short, in short-term due to its chemical constituent complexity
Interior therapeutic effect and chemical constituent vary widely.
《The research of Collunarium content and its chloramphenicol decomposition product detection method》In describe one kind
Collunarium, mainly by metronidazole and chloromycetin group at antibacterial, anti-inflammatory, promotion nasal cavity post-operative recovery
The effects that, the washing wound surface that is mainly used for after the surgery of nasal cavity such as nasosinusitis, nasal polyp.Under normal circumstances, the liquid system of chloramphenicol
During production and long-term storage hydrolysis, light degradation reaction can occur for agent.Its hydrolysate is mainly 1- p-nitrophenyls-
2- amino-1,3-propanediols (abbreviation Chloramphenicol eye drops), photolytic product is mainly paranitrobenzaldehyde.
To sum up, although collunarium for moistening bronchia mucosal have good application prospect, existing collunarium or
Uncertain therapeutic efficacy is cut, or short in storage time, and being greatly lowered for drug effect occurs in the short time.Based on this, a kind of curative effect is researched and developed
Collunarium that is definite and preserving property stabilization has important practical significance.
201711247446.4 disclose a kind of spray for treating allergic rhinitis, including Chinese medical extract, by weight
Number meter is measured, Chinese medical extract is mainly made of following raw material：20~40 parts of great Ye faint scent osmanthus, 15~25 parts of corydlis bungeana, asarum 5
~15 parts, 10~20 parts of Fructus Forsythiae, 5~15 parts of peppermint, 5~15 parts of Radix Glycyrrhizae, 5~15 parts of honeysuckle.Containing more in the traditional Chinese medicinal components
Kind traditional Chinese medicinal components, complicated component are used to be easy to aggravate allergic symptom when allergic rhinitis.
Invention content
In order to overcome the above-mentioned deficiencies of the prior art, the present invention provides a kind of collunarium slowing down Rhinitis Symptoms and its answers
With.The active constituent of the collunarium is by water-soluble mint extract, borneol and N- [(4- methyl piperazines base -1) methyl]-N- (2-
Tertiary butyl thiazole base -5)-niacinamide composition, have and slow down Rhinitis Symptoms effect well, is combined coptisine on this basis
The transdermal absorption factor of active component can be improved, and then enhances the therapeutic effect of collunarium.Collunarium curative effect of the present invention
Definitely, preparation stability is high, is appropriate for promoting and applying.
The present invention is achieved through the following technical solutions above-mentioned technique effect：
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by water-soluble mint extract 10-15 parts by weight, borneol
0.3-0.5 parts by weight, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide 0.4-1.2 weight
Part composition.
The preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms, the water-soluble mint extract includes：It will be big
Soybean cake impurity elimination smashes it through 40 mesh sieve, impregnates 30min with 10 times of amount pure water, 5% sodium hydrate regulator solution pH to 9- is added
10,80 DEG C of stirring extraction 1h are heated to, filter residue are soaked in 10 times of amount water after filtering, with food grade salts acid-conditioning solution pH value
It is 7, high temperature resistant type liquefaction a- amylase is added with the ratio of 3000U/100g dregs of beans, is heated to 80 DEG C of stirring enzymolysis 30min, rises
High-temperature keeps enzyme deactivation after this temperature 10min to 100 DEG C, is cooled to 60 DEG C, is centrifuged after 0.2% hydrogen peroxide for decoloration 4h is added, will
Filter residue pure water 2 times, centrifuge dripping, low temperature drying is up to water-soluble mint extract.
In collunarium described above, the borneol and N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiophenes
Oxazolyl -5)-niacinamide can be used prior art preparation obtain or commercially available purchase obtain.
The present invention has also carried out preferably the collunarium described above for slowing down Rhinitis Symptoms, and preferred inspection target is rhinitis
Alleviation degree, it has been found that as water-soluble mint extract, borneol and N- [(4- methyl piperazines base -1) methyl]-N-
It is stronger for the remission effect of rhinitis when the weight part ratio of (2- tertiary butyl thiazoles base -5)-niacinamide is 30: 1: 2.
As a kind of embodiment preferred for this invention, it has been found that on the basis of above-mentioned collunarium prescription
When adding with coptisine, the transdermal absorption factor of active constituent can be significantly improved, and significantly increase the stability of pharmaceutical preparation, one
Determine the degree of alleviation degree and the cleannes collunarium is enhanced in to(for) rhinitis.Preferably, the coptis in the collunarium
The weight ratio of alkali and water-soluble mint extract is 1: 100, and the stability highest of collunarium, transdermal efficiency are best at this time.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is redissolved water-soluble mint extract using physiological saline, is added thereto
Enter N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, vibrates and be uniformly mixed backward
Wherein be added coptisine, after mixing the pH of adjustment mixed liquor be 6.8-7.4 to get.
The preparation method of the collunarium as described above for slowing down Rhinitis Symptoms, the water-soluble mint extract and physiology
The weight ratio of brine is 1: 15-19, preferably 1: 17.
The present invention also provides the application of above-mentioned collunarium, the collunarium can be used for postoperative cleaning nasal cavity, and described washes
Nose agent has preferably moistening mucous membrane and cleaning effect, has very well with Mucous rehabilitation for the extravasated blood cleaning in postoperative nasal cavity
Effect.The embodiment of the present invention 9 show collunarium of the present invention have good postoperative nasal cavity cleaning effect, wherein treat 1 group and
2 groups of the apparent existing commercial product of nasal cavity cleaning effect is treated, while collunarium of the present invention has anti-inflammatory well and promotes
Wound healing effect, wound healing time are substantially reduced, wherein the wound healing time for treating 2 groups is smaller than 1 group for the treatment of.
The present invention also provides above-mentioned collunarium another kind application, the collunarium has good antiallergic effect, tool
Play the role of slowing down Rhinitis Symptoms well.The embodiment of the present invention 7 shows that each collunarium paraxylene of the present invention causes mouse otitis
All have good inhibiting effect.Wherein in embodiment 1- embodiments 3, the effect of embodiment 2 is preferable, for the more excellent of the present invention
Embodiment.But after combination coptisine (coptisine is 1: 100 with water-soluble mint extract), coptisine and other groups in prescription
Performance is divided to be significantly increased except significantly synergistic effect, therapeutic effect.But (join with water-soluble mint extract ratio when changing coptisine
Than embodiment 3 and Comparative Examples 4), inhibition then significantly reduces, this shows this synergistic effect and coptisine and water solubility
The weight ratio of mint extract is in close relations.Meanwhile should the result shows that, when lacking water-soluble mint extract or N- in prescription
[(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, inhibiting effect are also poor.The present invention is real
It applies example 8 and shows that collunarium of the present invention has apparent mitigation for Rhinitis Symptoms, wherein it is bright to treat 2 groups of effect
Aobvious to be better than 1 group for the treatment of, this, which shows coptisine is used in combination on the basis of prescription, can improve collunarium of the present invention and control rhinitis
Therapeutic effect.
The present invention has following technical advantage compared with prior art：
1) collunarium reasonable recipe of the present invention, Rhinitis Symptoms, which are alleviated, has significant therapeutic effect, at it
On the basis of be combined coptisine, each component has significant synergistic effect in terms of Rhinitis Symptoms alleviation.
2) collunarium of the present invention can not only anti-inflammatory and wound healing effect, wound healing time is significantly
It reduces, wherein combination coptisine wound healing time is smaller than 1 group for the treatment of.
3) collunarium component of the present invention is clear, easy to use and carry, will not when alleviating for Rhinitis Symptoms
Any side effect is generated, to improve compliance, enhances therapeutic effect.
Specific implementation mode
The present invention is further described below by way of specific embodiment, but the embodiment does not limit this hair in any way
The range of bright patent protection.
Embodiment 1
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 10 parts by weight of water-soluble mint extract, borneol 0.3
Parts by weight, 0.4 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 15 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
After mixing adjustment mixed liquor pH be 6.8-7.4 to get.
Embodiment 2
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 13 parts by weight of water-soluble mint extract, borneol 0.4
Parts by weight, 0.8 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 17 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
After mixing adjustment mixed liquor pH be 6.8-7.4 to get.
Embodiment 3
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 15 parts by weight of water-soluble mint extract, borneol 0.5
Parts by weight, 1.2 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 19 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
After mixing adjustment mixed liquor pH be 6.8-7.4 to get.
Embodiment 4
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 10 parts by weight of water-soluble mint extract, borneol 0.3
Parts by weight, 0.4 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, coptisine
0.1 part of composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 15 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
Be added coptisine thereto after mixing, after mixing the pH of adjustment mixed liquor be 6.8-7.4 to get.
Embodiment 5
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 13 parts by weight of water-soluble mint extract, borneol 0.4
Parts by weight, 0.8 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, coptisine
0.13 part of composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 17 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
Be added coptisine thereto after mixing, after mixing the pH of adjustment mixed liquor be 6.8-7.4 to get.
Embodiment 6
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 15 parts by weight of water-soluble mint extract, borneol 0.5
Parts by weight, 1.2 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, coptisine
0.15 part of composition.
A kind of preparation method of the above-mentioned collunarium for slowing down Rhinitis Symptoms comprising following steps：
Water-soluble mint extract is prepared first, is answered water-soluble mint extract using the physiological saline of 19 times of volumes
It is molten, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol, oscillation are added thereto
Be added coptisine thereto after mixing, after mixing the pH of adjustment mixed liquor be 6.8-7.4 to get.
Comparative Examples 1
Except in preparation prescription be free of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide
Outside, remaining prescription and preparation process are the same as embodiment 2.
Comparative Examples 2
In addition in preparation prescription without water-soluble mint extract, remaining prescription and preparation process are the same as embodiment 2.
Comparative Examples 3
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 13 parts by weight of water-soluble mint extract, borneol 0.4
Parts by weight, 0.8 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, coptisine
0.26 part of composition.
Comparative Examples 4
A kind of collunarium slowing down Rhinitis Symptoms, active constituent is by 13 parts by weight of water-soluble mint extract, borneol 0.4
Parts by weight, 0.8 parts by weight of N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, coptisine
0.065 part of composition.
Comparative example 1
It is prepared according to prescription and preparation process described in 201711247446.4 embodiments.
The influence that 7 collunarium of the present invention of embodiment inhibits the mouse ear delayed type hypersensitivity, DTH that dinitrofluorobenzene induces
The mouse ear delayed type hypersensitivity, DTH inhibiting effect that 1 collunarium of the present invention of table induces dinitrofluorobenzene
| Left ear weight (gram) | Auris dextra weight (gram) | The ear method of double differences (gram) | |
| Model control group | 0.0133±0.005 | 0.0280±0.008 | 0.0148±0.0006 |
| 1 group of embodiment | 0.0135±0.005 | 0.0198±0.010 | 0.0061±0.0006* |
| 2 groups of embodiment | 0.0133±0.004 | 0.0185±0.005 | 0.0052±0.0008* |
| 3 groups of embodiment | 0.0132±0.002 | 0.0197±0.007 | 0.0063±0.0005* |
| 4 groups of embodiment | 0.0134±0.005 | 0.0191±0.006 | 0.0057±0.0007 |
| 5 groups of embodiment | 0.0133±0.005 | 0.0173±0.010 | 0.0040±0.0006* |
| 6 groups of embodiment | 0.0131±0.004 | 0.0186±0.011 | 0.0055±0.0008* |
| 1 group of Comparative Examples | 0.0133±0.002 | 0.0234±0.014 | 0.0101±0.0005* |
| 2 groups of Comparative Examples | 0.0135±0.005 | 0.0253±0.012 | 0.0118±0.0007 |
| 3 groups of Comparative Examples | 0.0133±0.005 | 0.0212±0.009 | 0.0079±0.0006* |
| 4 groups of Comparative Examples | 0.0134±0.004 | 0.0224±0.013 | 0.0090±0.0008* |
| 1 group of comparative example | 0.0133±0.006 | 0.0251±0.009 | 0.0129±0.005 |
* is compared with model control group, P ＜ 0.01
* compared with model control group, P ＜ 0.05
According to the mouse ear delayed type hypersensitivity, DTH model of method structure dinitrofluorobenzene induction in existing literature, Zuo Erwei
Normal ear smears collunarium and reference preparation of the present invention, a concentration of 10mg/ml of each external preparation to auris dextra.Applying amount is
2ml/ ears.It the results are shown in Table 1.The experimental results showed that each collunarium paraxylene of the present invention causes mouse otitis to all have preferably
Inhibiting effect.Wherein in embodiment 1- embodiments 3, the effect of embodiment 2 is preferable, for the preferred embodiment of the present invention.But
After being combined coptisine (coptisine is 1: 100 with water-soluble mint extract), coptisine is with other components performance in prescription except aobvious
Synergistic effect is write, therapeutic effect significantly increases.But when change coptisine and water-soluble mint extract ratio (Comparative Examples 3
With Comparative Examples 4), inhibition then significantly reduces, this shows that this synergistic effect is extracted with coptisine and water-soluble peppermint
The weight ratio of object is in close relations.Meanwhile should the result shows that, when lacking water-soluble mint extract or N- [(4- methyl piperazines in prescription
Piperazine base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide, inhibiting effect is also poor.
Mitigation of 8 collunarium of the present invention of embodiment to Rhinitis Symptoms
Choose bouncing, mode of appearance, the performance without exception of behavior sign cavy 60, be randomly divided into control group, control
Treat 1 group and 2 groups for the treatment of.1 group of collunarium given described in embodiment 2 is treated, 2 groups of collunariums given described in embodiment 5 are treated.
Each group is respectively administered once sooner or later daily, successive administration 10d
Modelling：1. intraperitoneal injection：Ovalbumin (OVA) injection 30mg, aluminium hydroxide Al (OH) 330mg, jointly
It is dissolved in 1mL physiological saline and mixing suspension is made, modeling group cavy is injected intraperitoneally；1mL pairs of physiological saline is used simultaneously
Blank group is equally operated.The next day inject 1 time, co-injection 7 times.
2. Neulized inhalation：The OVA normal saline solutions for preparing 0.5%, are added into the atomization of Multifunction ultrasonic atomizer
In cup, 5 cavys (considering density) are put into transparent cavy collective box, are covered above with clean glass, by atomizer
Aerosol conduit imported in cavy collective box by aperture on glass cover, open atomizer, adjust aerosol flow, every batch of
10min or so, every batch of atomization quantity 10mL；Blank group is equally operated with physiological saline.Daily sucking 1 time, continuous 5 times.
3. collunarium stimulates：After modeling starts 3 days, collunarium is carried out with 2%OVA physiological salt liquids, one time a day, per side nostril
0.1mL, continuous 4 days.Modeling success after, the next day give OVA 1g/L collunariums to maintain the stimulation to schneiderian membrance.
Animal behavioral study：The sneeze number in cavy 5min is observed after each collunarium stimulation and scratches nose number.It observes knot
Fruit is respectively as shown in table 2 and table 3.
Influence of 2 collunarium of the present invention of table to sneeze number
| Group | 1d | 4d | 7d | 10d |
| Control group | 3.5±0.8 | 3.3±0.9 | 3.4±0.8 | 3.2±0.7 |
| Treat 1 group | 3.4±0.5 | 2.8±0.4 | 2.0±0.6 | 1.2±0.3 |
| Treat 2 groups | 3.2±0.6 | 2.4±0.1 | 1.4±0.3 | 0.5±0.2 |
Influence of 3 collunarium of the present invention of table to sneeze number
| Group | 1d | 4d | 7d | 10d |
| Control group | 10.6±1.5 | 11.3±2.1 | 10.7±1.8 | 10.7±1.6 |
| Treat 1 group | 10.4±1.5 | 7.8±1.4 | 6.0±0.6 | 3.2±0.3 |
| Treat 2 groups | 10.2±1.6 | 6.4±1.1 | 4.4±1.3 | 1.5±0.7 |
Collunarium of the present invention has apparent mitigation for Rhinitis Symptoms it can be seen from table 2 and table 3,
It wherein treats 2 groups with obvious effects and is better than 1 group for the treatment of, this shows that coptisine is used in combination on the basis of prescription can improve this hair
Therapeutic effect of the bright collunarium to rhinitis.
9 collunarium of the present invention of embodiment is to the clean effect of postoperative nasal cavity
The postoperative healing that will produce a large amount of extravasated blood and be related to nasal cavity wound of nasal cavity, in order to verify the nose of collunarium of the present invention
Chamber therapeutic effect selects nasal polyp or rhinitis patient with operation as 30 people of research object, is randomly divided into 3 groups, control group uses city
The collunarium sold treats 1 group of collunarium given described in embodiment 2, treats 2 groups of collunariums given described in embodiment 5.Respectively
It monitors wound healing time and nasal cavity cleaning degree, testing result is as follows.Wherein nasal cavity cleaning degree is commented with intuitive observation
Point, it is indicated using " ++++" " +++ " " ++ " "+" as its cleannes degree.When wound healing to use collunarium twice in succession
No extravasated blood outflow is used as criterion.
4 collunarium of the present invention of table is to the clean effect of postoperative nasal cavity
As can be seen from Table 4, collunarium of the present invention has good postoperative nasal cavity cleaning effect, wherein treating 1 group and controlling
2 groups of the apparent existing commercial product of nasal cavity cleaning effect is treated, while collunarium of the present invention has anti-inflammatory well and promotion wound
Face healing effect, wound healing time are substantially reduced, wherein the wound healing time for treating 2 groups is smaller than 1 group for the treatment of.
Claims (9)
1. a kind of collunarium slowing down Rhinitis Symptoms, active constituent is by water-soluble mint extract 10-15 parts by weight, borneol
0.3-0.5 parts by weight, N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide 0.4-1.2 weight
Part composition.
2. the collunarium according to claim 1 for slowing down Rhinitis Symptoms, which is characterized in that the water-soluble peppermint extraction
The preparation method of object includes：Soybean cake dregs impurity elimination is smashed it through into 40 mesh sieve, 30min is impregnated with 10 times of amount pure water, 5% hydrogen is added
Sodium oxide molybdena adjusts pH value of solution to 9-10, is heated to 80 DEG C of stirring extraction 1h, filter residue is soaked in 10 times of amount water after filtering, with food
It is 7 to adjust solution ph with grade hydrochloric acid, and high temperature resistant type liquefaction a- amylase is added with the ratio of 3000U/100g dregs of beans, is heated to
80 DEG C of stirring enzymolysis 30min, increase temperature to 100 DEG C, keep enzyme deactivation after this temperature 10min, be cooled to 60 DEG C, be added 0.2%
It is centrifuged after hydrogen peroxide for decoloration 4h, by filter residue pure water 2 times, centrifuge dripping, low temperature drying is up to water-soluble mint extract.
3. the collunarium according to claim 1 for slowing down Rhinitis Symptoms, which is characterized in that the water-soluble peppermint extraction
The weight part ratio of object, borneol and N- [(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide is
30∶1∶2。
4. the collunarium according to claim 1 for slowing down Rhinitis Symptoms, which is characterized in that further include in the collunarium
Coptisine.
5. the collunarium according to claim 4 for slowing down Rhinitis Symptoms, which is characterized in that coptisine in the collunarium
Weight ratio with water-soluble mint extract is 1: 100.
6. a kind of preparation method of any collunariums for slowing down Rhinitis Symptoms of claim 1-5 comprising following steps：
Water-soluble mint extract is prepared first, and water-soluble mint extract is redissolved using physiological saline, N- is added thereto
[(4- methyl piperazines base -1) methyl]-N- (2- tertiary butyl thiazoles base -5)-niacinamide and borneol vibrate after mixing thereto
Coptisine is added, after mixing the pH of adjustment mixed liquor be 6.8-7.4 to get.
7. the preparation method of the collunarium according to claim 6 for slowing down Rhinitis Symptoms, which is characterized in that described is water-soluble
Property mint extract and physiological saline weight ratio be 1: 15-19, preferably 1: 17.
8. any collunariums of claim 1-5 clean the application in nasal cavity after surgery.
9. application of any collunarium collunariums of claim 1-5 in slowing down Rhinitis Symptoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810425278.1A CN108671020A (en) | 2018-05-04 | 2018-05-04 | A kind of collunarium slowing down Rhinitis Symptoms and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810425278.1A CN108671020A (en) | 2018-05-04 | 2018-05-04 | A kind of collunarium slowing down Rhinitis Symptoms and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108671020A true CN108671020A (en) | 2018-10-19 |
Family
ID=63801960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810425278.1A Pending CN108671020A (en) | 2018-05-04 | 2018-05-04 | A kind of collunarium slowing down Rhinitis Symptoms and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108671020A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011439A (en) * | 2007-01-05 | 2007-08-08 | 柴俊 | Collunarium or spraying preparation for treating nasal cavity inflammation and its preparation method |
| CN103735581A (en) * | 2014-01-17 | 2014-04-23 | 刘少华 | Care solution for cleaning nasal cavity and preparation method of care solution |
| CN107501251A (en) * | 2017-09-14 | 2017-12-22 | 刘双伟 | A kind of compound and its application in Claritin is prepared |
-
2018
- 2018-05-04 CN CN201810425278.1A patent/CN108671020A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011439A (en) * | 2007-01-05 | 2007-08-08 | 柴俊 | Collunarium or spraying preparation for treating nasal cavity inflammation and its preparation method |
| CN103735581A (en) * | 2014-01-17 | 2014-04-23 | 刘少华 | Care solution for cleaning nasal cavity and preparation method of care solution |
| CN107501251A (en) * | 2017-09-14 | 2017-12-22 | 刘双伟 | A kind of compound and its application in Claritin is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105326786A (en) | Nasal irrigant composition and preparation method thereof | |
| CN104208410A (en) | Traditional Chinese medicine preparation for improving eyesight and protecting pupil | |
| CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN108686026A (en) | A kind of licorice ballonflower particle and preparation method thereof for cough with lung heat | |
| CN108635368A (en) | A kind of eye-drops preparations containing small molecule dendrobium polysaccharide and preparation method and application | |
| CN102579687B (en) | Nasal cavity Chinese medicinal washing fluid for rhinitis | |
| CN104857287B (en) | Traditional Chinese medicine eye drops for treating xerophthalmia and preparation method thereof | |
| CN108671020A (en) | A kind of collunarium slowing down Rhinitis Symptoms and its application | |
| CN103127383B (en) | Traditional Chinese medicine for treating children allergic rhinitis | |
| CN107259024A (en) | A kind of medicine-food two-purpose ganoderma lucidum ginseng tea and preparation method thereof | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN104027397B (en) | A kind of preparation method of integration of edible and medicinal herbs plant extract anti-sensitizer and application | |
| CN105395587A (en) | Traditional Chinese medicine reagent used for treating nose problems and preparation method thereof | |
| CN105343274A (en) | Drug combination having inflammation diminishing and cough relieving functions | |
| CN108785559A (en) | A kind of drug and preparation method thereof for treating respiratory tract infection | |
| CN106389473A (en) | Drug for treating allergic rhinitis and preparation method thereof | |
| CN104306764B (en) | A kind of Chinese medicine compound prescription spray for being used to control rhinitis | |
| CN109965052A (en) | A kind of health protection tea and its preparation process | |
| CN111419883B (en) | Preparation method of nasal spray for treating allergic rhinitis | |
| CN103520707B (en) | A kind of beneficial bacterium controls the compositions that bacterium prevention and therapy gynaecologic reproductive system infects | |
| CN107375693A (en) | A kind of traditional Chinese medicine health care product for strengthening immunity of organisms and preparation method thereof | |
| CN107007823A (en) | It is a kind of to be used to treat medicine of rhinitis and preparation method thereof | |
| CN106822671A (en) | medicine for treating conjunctivitis | |
| CN104258361A (en) | Traditional Chinese medicine composition for treating infantile asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181019 |